In order to increase the stability of RA in human body and the selectivity against RARs, synthetic retinoids have been developed for clinical trials of neurological diseases, for example, Alzheimer’s disease (Wołoszynowska-Fraser et al., 2020). The gene discussed is RARS1; the disease is early-onset autosomal dominant Alzheimer disease.